Compare SUNS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | CGTX |
|---|---|---|
| Founded | 2023 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.6M | 132.4M |
| IPO Year | N/A | 2021 |
| Metric | SUNS | CGTX |
|---|---|---|
| Price | $9.69 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.50 | $2.88 |
| AVG Volume (30 Days) | 94.9K | ★ 957.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | ★ 12.28% | N/A |
| EPS Growth | ★ 1112.46 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $19,384,703.00 | N/A |
| Revenue This Year | $174.58 | N/A |
| Revenue Next Year | $60.45 | N/A |
| P/E Ratio | $8.95 | ★ N/A |
| Revenue Growth | ★ 2540.16 | N/A |
| 52 Week Low | $7.80 | $0.22 |
| 52 Week High | $14.87 | $3.83 |
| Indicator | SUNS | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 42.87 |
| Support Level | $10.06 | $1.37 |
| Resistance Level | $10.13 | $1.62 |
| Average True Range (ATR) | 0.30 | 0.12 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 33.15 | 15.36 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.